Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Focuses Latest Warnings on Accountability and Root Cause

This article was originally published in The Gold Sheet

Executive Summary

Quest for accountability and root cause seen in latest FDA warning letters. FDA, Congress pressure McNeil, J&J. 'Phantom recall' debated. Is propofol too hard for Teva, Hospira to make? Perrigo raked over tablet mix-ups. Braintree learns to fear spiders. Merck unit goes OOS. Splitting hairs over Shamrock's tablet splitting? Pierre Fabre: Three batches and you're out?

You may also be interested in...



Perrigo Applies Crime Scene Investigation Model to Improve Quality Control

Perrigo quality control managers emphasize immediate investigations of low-risk incidents and forward-looking remediation in the firm’s new corrective and preventive actions strategy.

Perrigo Applies Crime Scene Investigation Model to Improve Quality Control

Perrigo quality control managers emphasize immediate investigations of low-risk incidents and forward-looking remediation in the firm’s new corrective and preventive actions strategy.

Another Busy Year of Drug Recalls Led to Shortages of Injectables

Manufacturers recalled more drug products from the U.S. market in 2010 than they had in any year but 2009.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS000507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel